Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Plans R&D, Manufacturing Expansion In Asia

This article was originally published in PharmAsia News

Executive Summary

In another indication of big pharma's expanding interest in Asia, Pfizer announced Nov. 30 that it will seek to increase the amount of R&D and manufacturing it does in that part of the world

You may also be interested in...



Japan's Otsuka Holds Talks With Korean Government On R&D Project

SEOUL - The Korean unit of Japan's Otsuka Pharmaceuticals is holding negotiations with South Korea's Ministry for Heath, Welfare and Family Affairs on investing in drug research and development, and the two sides could soon sign a memorandum of understanding, according to a Korea Otsuka executive

Japan's Otsuka Holds Talks With Korean Government On R&D Project

SEOUL - The Korean unit of Japan's Otsuka Pharmaceuticals is holding negotiations with South Korea's Ministry for Heath, Welfare and Family Affairs on investing in drug research and development, and the two sides could soon sign a memorandum of understanding, according to a Korea Otsuka executive

More Than Half Of Trials Conducted In South Korea Led By Pfizer

SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel